Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease

Bone Marrow Transplantation volume 26, pages 445–449 (2000)Cite this article

Abstract

Although allogeneic transplantation can be curative for patients with sickle cell disease, the toxicity of conditioning regimens has precluded its use in adults with significant end-organ damage. Newer conditioning regimens have been developed that are less toxic and that may broaden the applicability of allogeneic transplantation in this disorder. We report two adults with end-stage sickle cell disease, who underwent allogeneic transplantation from an HLA-identical sibling donor after conditioning with fludarabine/melphalan and ATG. Both patients had been extensively transfused and one had multiple RBC antibodies. One of the patients also had end-stage renal disease, and was dialysis dependent. Engraftment occurred promptly in both patients. Both achieved 100% donor chimerism and both were free of pain crises after transplant. The first patient died of a respiratory failure related to chronic graft-versus-host disease (GVHD) on day 335 after transplantation. The second patient developed severe gastro-intestinal GVHD and TTP and died on day 147 after transplantation. Conditioning with fludarabine/melphalan and ATG followed by allogeneic stem cell transplantation resulted in prompt and reliable engraftment in adults with end-stage sickle cell disease. The incidence of severe GVHD was unacceptably high and may be related to the ethnicity of the patients or to the inflammatory state associated with pre-existing sickle cell disease. Bone Marrow Transplantation (2000) 26, 445–449.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Walters MC, Patience M, Leisenring W et al. Bone marrow transplantation for sickle cell disease New Engl J Med 1996 335: 369–376

    Article  CAS  PubMed  Google Scholar 

  2. Vermylen C, Cornu G, Ferster A et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium Bone Marrow Transplant 1998 22: 1–6

    Article  CAS  PubMed  Google Scholar 

  3. Lee A, Thomas P, Cupidore L et al. Improved survival in homozygous sickle cell disease: lessons from a cohort study Br Med J 1995 311: 1600–1602

    Article  CAS  Google Scholar 

  4. Platt OS, Guinan EC . Bone marrow transplantation in sickle cell anemia – the dilemma of choice New Engl J Med 1996 335: 426–427

    Article  CAS  PubMed  Google Scholar 

  5. Platt OS, Brambilla DJ, Rosses WF et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death New Engl J Med 1994 330: 1639–1644

    Article  CAS  PubMed  Google Scholar 

  6. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536

    CAS  PubMed  Google Scholar 

  7. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

  8. Giralt S, Cohen R, Mehra et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for myeloablative conditioning Blood 1997 90: (Suppl. 1) 1853 (Abstr.)

    Google Scholar 

  9. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and mini-dose methotrexate for prevention of acute graft-vs-host disease after matched unrelated donor transplantation Blood 1996 88: 4383–4389

    CAS  PubMed  Google Scholar 

  10. Przepiorka D, Anderlini P, Ippoliti C et al. Risk factors for acute graft-versus-host disease in allogeneic blood stem cell transplant recipients Blood 1997 90: (Suppl. 1) 441 (Abstr.)

    Google Scholar 

  11. Wall SM, Johansen MJ, Molony DA et al. Effective clearance of methotrexate using high-flux hemodialysis membranes Am J Kidney Dis 1996 28: 846–854

    Article  CAS  PubMed  Google Scholar 

  12. van Besien K, Thall P, Korbling M et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, cyclophosphamide. Experience in 44 consecutive patients Biol Blood Marrow Transplant 1997 3: 150–156

    CAS  PubMed  Google Scholar 

  13. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts Blood 1995 85: 1659–1665

    CAS  PubMed  Google Scholar 

  14. Bartholomew AM, Sher D, Sosler S et al. Stem cell transplantation for a highly sensitized patient Transplantation 1999 67: s14 (Abstr.)

    Article  Google Scholar 

  15. Lucarelli G, Clift RA, Galimberti M et al. Bone marrow transplantation in adult thalassemic patients Blood 1999 93: 1164–1167

    CAS  PubMed  Google Scholar 

  16. van Besien K, Kodish E, Devine S et al. Attitudes toward allogeneic transplantation among adults with sickle cell disease Blood 1999 94: (Suppl. 1) 27b (Abstr.)

    Google Scholar 

  17. Van Besien KW, Demuynck H, LeMaistre CF et al. High dose melphalan allows durable engraftment of allogeneic bone marrow Bone Marrow Transplant 1995 15: 321–323

    CAS  PubMed  Google Scholar 

  18. Singhal S, Powles R, Treleaven J et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility Bone Marrow Transplant 1996 18: 1049–1057

    CAS  PubMed  Google Scholar 

  19. Salloum E, Jillella AP, Nadkarni R et al. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation Cancer 1998 82: 1506–1512

    Article  CAS  PubMed  Google Scholar 

  20. Przepiorka D, Ippoliti C, Khouri I et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus Transplantation 1996 62: 1806–1810

    Article  CAS  PubMed  Google Scholar 

  21. Bensinger W, Martin P, Clift RA et al. A prospective randomized trial of peripheral blood stem cells or bone marrow for patients undergoing allogeneic transplantation for hematologic malignancies Blood 1999 94: (Suppl. 1) 368a (Abstr. 1637)

    Google Scholar 

  22. Przepiorka D, Ippoliti C, Khouri I et al. Microdose methotrexate vs methylprednisolone in combination with tacrolimus for prevention of acute graft-vs-host disease (gvhd) after allogeneic blood stem cell transplantation Blood 1996 88: (Suppl. 1) 418a (Abstr.)

    Google Scholar 

  23. Giralt S, Khouri I, Braunschweig I et al. Melphalan and purine analog containing preparative regimens. Less intensive conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 1999 94: (Suppl. 1) 564a (Abstr. 2518)

    Google Scholar 

  24. Klingemann HG, Deeg HJ, Self S et al. Is race a risk factor for allogeneic marrow transplantation? Bone Marrow Transplant 1986 1: 87–94

    CAS  PubMed  Google Scholar 

  25. Easaw SJ, Lake DE, Beer M et al. Graft-versus-host disease. Possible higher risk for African American patients Cancer 1996 78: 1492–1497

    Article  CAS  PubMed  Google Scholar 

  26. Graido-Gonzalez E, Doherty JC, Bergreen EW et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive crisis Blood 1998 92: 2551–2555

    CAS  PubMed  Google Scholar 

  27. Ferrara JLM, Antin JH . The pathophysiology of graft vs host disease. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic Cell Transplantation, 2 edn Blackwell Sciences: Malden 1999 pp. 305–315

  28. Bredeson C, Leger C, Sutherland H et al. Bone marrow versus peripheral blood allografts: an evaluation of the donor experience in a Canadian multicentre randomized trial Blood 1999 94:: (Suppl. 1) 163a (Abstr. 712)

    Google Scholar 

  29. McSweeney PA, Storb R . Mixed chimerism: preclinical studies and clinical applications Biol Blood Marrow Transplant 1999 5: 192–203

    Article  CAS  PubMed  Google Scholar 

  30. Urbano-Ispizua A, Rozman C, Martinez C et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood Blood 1997 89: 3967–3973

    CAS  PubMed  Google Scholar 

  31. Walters MC, Patience M, Leisenring W et al. Barriers to bone marrow transplantation for sickle cell anemia Biol Blood Marrow Transplant 1996 2: 100–104

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was sponsored in part by a grant from the Berlex company.

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology University of Illinois College of Medicine, Chicago, Illinois, USA

    K van Besien, A Bartholomew, W Stock, D Peace, S Devine, D Sher, J Sosman, Y-H Chen, M Koshy & R Hoffman

Authors
  1. K van Besien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Bartholomew
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Stock
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Peace
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Sher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Sosman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y-H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Koshy
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Besien, K., Bartholomew, A., Stock, W. et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 26, 445–449 (2000). https://doi.org/10.1038/sj.bmt.1702518

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702518

Keywords

This article is cited by

Search

Advanced search

Quick links